Supplementary Materials

Supplementary Material for:

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

Rizwan Romee, Maximillian Rosario, Melissa M. Berrien-Elliott, Julia A. Wagner, Brea A. Jewell, Timothy Schappe, Jeffrey W. Leong, Sara Abdel-Latif, Stephanie E. Schneider, Sarah Willey, Carly C. Neal, Liyang Yu, Stephen T. Oh, Yi-Shan Lee, Arend Mulder, Frans Claas, Megan A. Cooper, Todd A. Fehniger*

*Corresponding author. Email: tfehnige{at}

Published 21 September 2016, Sci. Transl. Med. 8, 357ra123 (2016)
DOI: 10.1126/scitranslmed.aaf2341

This PDF file includes:

  • Materials and Methods
  • Clinical vignettes
  • Fig. S1. Reduction of memory-like NK cell cytotoxicity against K562 leukemia cells by blockade of NKG2D or DNAM-1.
  • Fig. S2. Mass cytometry gating strategies.
  • Fig. S3. Phenotypic marker expression on viSNE gated control and memory-like NK cells.
  • Fig. S4. Enhanced effector responses of memory-like NK cells compared to control-treated NK cells.
  • Fig. S5. Schema of allogeneic memory-like NK cell phase 1 clinical trial (NCT01898793).
  • Fig. S6. Distribution of BM blast percentages and donor NK cell numbers sorted by clinical outcomes.
  • Fig. S7. Chemokine receptor expression on control versus IL-12, IL-15, and IL-18–preactivated human NK cells.
  • Table S1. NK cell phenotypic mass cytometry panel design, reagents, and clustering usage.
  • Table S2. NK cell functional mass cytometry panel design, reagents, and clustering usage.
  • Table S3. Characteristics of normal donors used in mass cytometry functional experiments.
  • Table S4. Characteristics of AML samples used for in vitro NK cell functional assays.
  • Table S5. Patient HLA and donor KIR characteristics for evaluable donor-patient pairs treated in the phase 1 clinical trial.
  • Table S6. Flow cytometry mAbs.
  • Reference (38)

[Download PDF]